Guardant Health, Inc. Stock 12‑Month Price Target Raised to $191.09, Implies 25% Upside
Analyst estimates for Guardant Health, Inc. show its average 12-month price target increased from $177 to $191.09, with a range of $125 to $225 per share, according to FactSet. Based on the Jul. 30 closing price, the target implies about 25% upside. The consensus rating remains “Buy” (25 Buys, 2 Holds, 2 Sells) across 29 analysts.
How this was made
The 30-second read
Why it matters
A higher consensus target can attract incremental dip-buying or momentum flows, but without new disclosed fundamentals it is unlikely to be a standalone driver of a large repricing.
Market read
Traders get a quick read on Street sentiment via the consensus target update, but there is no new operational or clinical catalyst in the text.
What to watch
The article does not state what changed in the underlying assumptions (revenue, margins, test volumes, reimbursement, or trial readouts), so traders should verify whether any new fundamental driver exists elsewhere.
Background
The piece summarizes FactSet-derived analyst consensus for Guardant Health, focusing on the updated average 12-month price target and rating mix.
Ticker impact
Guardant Health’s average 12-month analyst price target rose from $177 to $191.09, implying about 25% upside from the Jul. 30 close.
Mild positive bias for sentiment, with limited fundamental follow-through unless tied to new earnings, trial, or guidance.
The only disclosed change is the consensus price target range and maintained “Buy” rating; no new operational or regulatory catalyst is described.
Market effects
Limited read-through to oncology diagnostics/precision medicine peers because the article is purely a consensus target update.
None indicated.
None indicated.
Counterpoint
Price-target revisions may reflect model recalibration rather than new Guardant-specific catalysts, so the stock may not follow the implied upside.
Key entities
- public_companyGuardant Health, Inc.
Subject of the article, with updated analyst average 12-month price target to $191.09 and maintained consensus “Buy” rating.
